| HGNC approved symbol | BRCA2 |
| HGNC ID | HGNC:1101 |
| HGNC approved name | breast cancer 2, early onset |
| Entrez gene ID | GeneID:675 (SSTAR profile) |
| UniProt AC (human) | P51587 |
| UniProt ID (human) | BRCA2_HUMAN |
| Pfam domains | BRCA2 PF00634 (1002-1036, 1216-1244, 1424-1452, 1521-1548, 1665-1847, 1842-1867, 1974-2003, 2054-2083) BRCA-2_helical PF09169 (2476-2667) BRCA-2_OB1 PF09103 (2669-2798) BRCA2DBD_OB2 PF21318 (2804-2863, 2969-3034) Tower PF09121 (2831-2868) BRCA-2_OB3 PF09104 (3053-3189) domain PF22687 (3270-3382) |
| MGI symbol | Brca2 |
| MGI ID | MGI:109337 |
| UniProt AC (mouse) | P97929 |
| UniProt ID (mouse) | BRCA2_MOUSE |
| HGNC gene family tag | FANC |
| HGNC gene family description | Fanconi anemia, complementation groups |
| Function | Histone modification write |
| Modification | Histone acetylation |
| PMID for information on function | PMID:9619837 |
| Protein complex | BRCC |
| Target molecule | histone, DNA |
| Target entity | H3, H4, ssDNA |
| Product | # |
| PMID for information on target | PMID:9619837 |
| Comment | BRCA2 proteins acetylate primarily H3 and H4 of free histones. This suggests that HAT activity of BRCA2 may play an important role in the regulation of transcription and tumor suppressor function. |
| Status of entry | # |
| Expression range: | 0.0 to 109.86 |
| Mean expression: | 10.46 ± 12.79 |
| Median expression: | 5.95 |